Drug intelligence / Profile preview

follitropin delta + triptorelin

Development stage: Unknown
Lead developer: Ferring Pharmaceuticals
Modality: Recombinant Proteins and Enzymes, Peptides, Small Molecules
Administration: Subcutaneous, Intramuscular

Overview

FE 999049 (follitropin delta) is a novel recombinant human follicle-stimulating hormone (rFSH) developed by Ferring Pharmaceuticals and marketed under the brand name REKOVELLE. It is indicated for controlled ovarian stimulation to develop multiple follicles in women undergoing assisted reproductive technologies such as in vitro fertilization (IVF) or intracytoplasmic sperm injection (ICSI). FE 999049 is dosed individually based on body weight and serum anti-Müllerian hormone levels[5][6]. Triptorelin is a synthetic decapeptide agonist analog of luteinizing hormone-releasing hormone (LHRH), classified as a gonadotropin-releasing hormone (GnRH) agonist. It acts by initially stimulating and then suppressing pituitary secretion of LH and FSH after chronic administration[3][7]. The combination of follitropin delta with triptorelin may be used in protocols for ovarian stimulation where GnRH agonists are employed to prevent premature ovulation.

Brand names: REKOVELLETrelstarTriptodurDecapeptyl
Other names: recombinant human follicle-stimulating hormone + triptorelin

Targets

FSHR (Follicle-stimulating hormone receptor)GnRHR (Gonadotropin-releasing hormone receptor)

Beyond the preview

Go deeper on follitropin delta + triptorelin.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on follitropin delta + triptorelin.

Explore the full profile